- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 31.10. | Medical group advises against leucovorin for autism | ||
| 31.10. | "Significant shift" as NICE widens prostate cancer drug use | ||
| 31.10. | AZ trumpets results for new injectable C5 drug for gMG | ||
| 31.10. | MSD still seeking deals 'with urgency' after Verona takeover | ||
| 31.10. | Electra banks $183m for sHLH drug, and other biofinancings | ||
| 30.10. | Lilly climbs on stellar GLP-1 drug sales gain | ||
| 30.10. | Thermo bids $8.9bn for clinical trial data firm Clario | ||
| 30.10. | FDA plan will cut testing requirements for biosimilars | ||
| 30.10. | Novo tries to push Pfizer aside with $9bn bid for Metsera | ||
| 30.10. | As UK mulls prostate cancer screening, study shows benefit | ||
| 29.10. | MSD, Eisai abandon combination trial in liver cancer | ||
| 29.10. | BridgeBio two for two as rare disease drug aces ph3 trial | ||
| 29.10. | Specialty meds lift GSK's outlook in Walmsley's swan song | ||
| 29.10. | Falling flu vaccine sales in US stall CSL's Seqirus spinout | ||
| 29.10. | Lilly partners NVIDIA to build 'most powerful' supercomputer | ||
| 28.10. | Texas sues J&J, Kenvue over Tylenol autism claim | ||
| 28.10. | Campaign seeks to plug HIV care gap for UK women | ||
| 28.10. | MapLight shares track up after $251m IPO | ||
| 28.10. | GSK strikes again, adding COPD candidate in $745m deal | ||
| 28.10. | Novartis' new drugs outweigh Entresto decline in Q3 | ||
| 27.10. | CRISPR biotech Intellia plummets as trial paused for safety | ||
| 27.10. | Organon CEO resigns over 'improper' contraceptive sales | ||
| 27.10. | As Blenrep returns, GSK adds another ADC to cancer pipeline | ||
| 27.10. | Pressure rises on Novo as Innovent drug tops Ozempic | ||
| 27.10. | Novartis makes $12bn wager on RNA drugs with Avidity buy |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .